JAMA Oncology

Oncology & Cancer

Normalized post-op CEA may help predict colon cancer prognosis

(HealthDay)—Colon cancer patients with elevated preoperative carcinoembryonic antigen (CEA) levels that normalize after resection are not at increased risk for poor prognosis, according to a study published online Dec. ...

Oncology & Cancer

Liquid biopsy results differed substantially between two providers

Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Oncology & Cancer

No increase in seizure incidence with enzalutamide in mCRPC

(HealthDay)—For patients with metastatic castration-resistant prostate cancer (mCRPC) with at least one risk factor for seizure at baseline, treatment with enzalutamide is not associated with increased incidence of seizure, ...

Oncology & Cancer

Differences in cancer survival by type of insurance

(HealthDay)—From 1997 to 2014, improvements in cancer survival were mainly limited to patients with private or Medicare insurance, according to a study published online Nov. 30 in JAMA Oncology.

Oncology & Cancer

Heterogeneity of PET/CT imaging phenotype prognostic in mCRPC

(HealthDay)—Metastatic castration-resistant prostate cancer (mCRPC) has heterogeneity in positron emission tomography (PET)/computed tomography (CT) imaging phenotype, which has clinical relevance, according to a study ...

page 40 from 40